Jonathan Chang
Stock Analyst at Leerink Partners
(0.61)
# 4,074
Out of 5,056 analysts
81
Total ratings
29.33%
Success rate
-19.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $8.74 | +48.74% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $20.48 | +266.21% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $30.32 | -10.95% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $38.06 | +94.43% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $21.80 | -49.54% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $11.45 | +345.41% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $6.24 | +1,101.92% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $6.47 | +672.80% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $70.58 | -57.50% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.54 | +679.22% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $27.54 | +1,170.88% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $10.32 | +151.94% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $11.08 | +152.71% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $16.02 | +230.84% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $8.74
Upside: +48.74%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $20.48
Upside: +266.21%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $30.32
Upside: -10.95%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $38.06
Upside: +94.43%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $21.80
Upside: -49.54%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $11.45
Upside: +345.41%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $6.24
Upside: +1,101.92%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $6.47
Upside: +672.80%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $70.58
Upside: -57.50%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.54
Upside: +679.22%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $27.54
Upside: +1,170.88%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $10.32
Upside: +151.94%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $11.08
Upside: +152.71%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $16.02
Upside: +230.84%